Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis
Status:
Unknown status
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the change in visual activity of ranibizumab to
Photodynamic Therapy (PDT)in patients with choroidal neovascularization (CNV) secondary to
presumed ocular histoplasmosis